Potential for Glembatumumab Vedotin in TNBC

Dr. Cynthia Ma on the METRIC Trial in Triple-Negative Breast CancerПодробнее

Dr. Linda Vahdat on Glembatumumab Vedotin as a Treatment in Triple Negative Breast CancerПодробнее

The Potential of Immunotherapy in TNBCПодробнее

Antibody-Drug Conjugates for TNBCПодробнее

The importance of a biomarker-directed approach in triple-negative breast cancerПодробнее

New directions in immunotherapy for improving outcomes in TNBCПодробнее

Antibody-Drug Conjugates in Treating TNBCПодробнее

Current Progress and Future With Glembatumumab Vedotin in TNBCПодробнее

Potential Evolutions in the TNBC Treatment ParadigmПодробнее

Challenges in TNBCПодробнее

Educational Sessions: "Management of special subtypes of TNBC"Подробнее

Optimal chemotherapy combinations in TNBC gBRCA subtypesПодробнее

Biomarker-driven therapies for triple-negative breast cancerПодробнее

Immunological signatures to predict outcomes in patients with TNBCПодробнее

Comparing 3 Types of Targeted Therapies for Triple-Negative Breast CancerПодробнее

Treatments Under Investigation for Metastatic TNBCПодробнее

Emerging immunotherapy beyond checkpoint inhibitors for TNBCПодробнее

IMpassion130: immunotherapy for TNBCПодробнее

Expert Discusses The Value of Combination Treatment in TNBC TreatmentПодробнее